These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28498006)

  • 1. Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
    Baran A; Myśliwiec H; Szterling-Jaworowska M; Kiluk P; Świderska M; Flisiak I
    J Dermatolog Treat; 2018 Feb; 29(1):19-23. PubMed ID: 28498006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum irisin levels in patients with psoriasis.
    Baran A; Myśliwiec H; Kiluk P; Świderska M; Flisiak I
    J Dermatolog Treat; 2017 Jun; 28(4):304-308. PubMed ID: 27786588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels.
    Baran A; Świderska M; Myśliwiec H; Flisiak I
    J Dermatolog Treat; 2017 Mar; 28(2):136-140. PubMed ID: 27165470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40.
    Ataseven A; Kesli R
    G Ital Dermatol Venereol; 2016 Jun; 151(3):244-50. PubMed ID: 25279492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.
    Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
    Mediators Inflamm; 2017; 2017():9538451. PubMed ID: 28932021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels.
    Baran A; Swiderska M; Flisiak I
    J Dermatolog Treat; 2016; 27(2):114-9. PubMed ID: 26293108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.
    Baran A; Świderska M; Bacharewicz-Szczerbicka J; Myśliwiec H; Flisiak I
    Lipids; 2017 Jan; 52(1):51-60. PubMed ID: 27864793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
    Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis.
    Kong Y; Zhang S; Su X; Peng D; Su Y
    Postgrad Med; 2019 Aug; 131(6):405-412. PubMed ID: 31298974
    [No Abstract]   [Full Text] [Related]  

  • 10. Atherosclerosis, some serum inflammatory markers in psoriasis.
    Alpsoy S; Akyuz A; Erfan G; Akkoyun DC; Topcu B; Guzel S; Kaya S; Kulac M
    G Ital Dermatol Venereol; 2014 Apr; 149(2):167-75. PubMed ID: 24819636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy.
    Abu El-Hamd M; Adam El Taieb M; Mahmoud AA; Mahmoud Samy O
    J Dermatolog Treat; 2019 Sep; 30(6):545-548. PubMed ID: 30482111
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea sindrome.
    Mutlu LC; Tülübaş F; Alp R; Kaplan G; Yildiz ZD; Gürel A
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4161-4166. PubMed ID: 29028081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?
    Erfan G; Guzel S; Alpsoy S; Rifaioglu EN; Kaya S; Kucukyalcın V; Topcu B; Kulac M
    Mol Cell Biochem; 2015 Feb; 400(1-2):207-12. PubMed ID: 25421412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment.
    Khashaba SA; Attwa E; Said N; Ahmed S; Khattab F
    Dermatol Ther; 2021 Jan; 34(1):e14606. PubMed ID: 33249724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome.
    El-Hadidi H; Samir N; Shaker OG; Otb S
    Arch Dermatol Res; 2014 Apr; 306(3):239-45. PubMed ID: 24052155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings.
    Ahmed SF; Attia EA; Saad AA; Sharara M; Fawzy H; El Nahrery EM
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):682-8. PubMed ID: 25087779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome.
    Akboğa MK; Yalçın R; Şahinarslan A; Yılmaz Demirtaş C; Paşaoğlu H; Abacı A
    Anatol J Cardiol; 2016 Dec; 16(12):953-958. PubMed ID: 27443476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
    Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
    Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study.
    Conrozier T; Carlier MC; Mathieu P; Colson F; Debard AL; Richard S; Favret H; Bienvenu J; Vignon E
    Ann Rheum Dis; 2000 Oct; 59(10):828-31. PubMed ID: 11005786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.